Denver, CO (PRWEB) March 27, 2013
The prescription drug safety advocates at DrugRisk.com are announcing new information on the site for patients taking the blood thinner Pradaxa for atrial fibrillation. A new study presented this month has again raised questions over whether the drug has dangerous internal bleeding risks.
At DrugRisk, our goal is to improve the safety of prescription drug consumers by providing the latest alerts, recalls, studies and legal news. Patients with clear information can discuss side effect options with their doctor and decide if they need legal advice.
Information on the site shows health experts still disagree about the danger of Pradaxa internal bleeding. The FDA recently issued an advisory stating Pradaxa had the same risks as warfarin*. However, the Institute for Safe Medication Practices has ranked blood thinners like Pradaxa among the most dangerous drugs, and warned that patients suffering bleeding on Pradaxa are almost 5 times as likely to die than those with bleeding while taking warfarin**.
Now, DrugRisk has added a study from the University of Illinois at Chicago presented to the American College of Cardiology last week which warned that the data used by the FDA may be flawed, and the risk for bleeding from Pradaxa may be higher than previously thought***.
Already, more than 260 patients have filed a Pradaxa lawsuit over allegations of internal bleeding, which have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled
Copyright©2012 Vocus, Inc.
All rights reserved